KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q3 2025 value amounting to 0.28%.

  • CRISPR Therapeutics AG's Return on Capital Employed fell 1300.0% to 0.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.28%, marking a year-over-year decrease of 1300.0%. This contributed to the annual value of 0.22% for FY2024, which is 1100.0% down from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Return on Capital Employed stood at 0.28% for Q3 2025, which was down 1300.0% from 0.28% recorded in Q2 2025.
  • CRISPR Therapeutics AG's Return on Capital Employed's 5-year high stood at 0.19% during Q2 2021, with a 5-year trough of 0.31% in Q4 2022.
  • Its 5-year average for Return on Capital Employed is 0.14%, with a median of 0.22% in 2024.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Return on Capital Employed soared by 3700bps in 2021 and then plummeted by -4500bps in 2022.
  • CRISPR Therapeutics AG's Return on Capital Employed (Quarter) stood at 0.14% in 2021, then tumbled by -321bps to 0.31% in 2022, then surged by 65bps to 0.11% in 2023, then plummeted by -99bps to 0.22% in 2024, then tumbled by -32bps to 0.28% in 2025.
  • Its last three reported values are 0.28% in Q3 2025, 0.28% for Q2 2025, and 0.23% during Q1 2025.